Tardelli et al. (2019) reported that inhibiting MAGL protects against liver injury and may be considered a potential therapy for sclerosing cholangitis. In addition, Xiang et al. (2018) reported that MAGL delays tumor progression by regulating activation of cannabinoid receptor 2-dependent macrophages. The latest study indicated that inhibiting MAGL protects against bone disease caused by primary bone cancer and bone metastasis (Marino et al., 2019). The gene discussed is MGLL; the disease is bone neoplasm.